Last reviewed · How we verify

NCT05704569

Prediction of Primary Cardiovascular Events Using the Multimarker Approach

Completed Last updated 15 March 2023
What this trial tests

trial testing measurement of multiple biomarkers in Cardiovascular Diseases in 1,500 participants. Completed in 1 December 2022.

Timeline
1 June 2014
Primary endpoint
1 March 2020
1 December 2022

Quick facts

Lead sponsorKaraganda Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,500
Start date1 June 2014
Primary completion1 March 2020
Estimated completion1 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

Karaganda Medical University

Who can join

Adults 25 to 65, any sex, with Cardiovascular Diseases or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study of biochemical risk factors for cardiovascular diseases is important not only for analysis, but also for preventive measures, given that changes in the level of biomarkers can be detected before the first clinical manifestations of CVD. Accordingly, patients at high CV risk may have additional motivation to lead a healthy lifestyle. In addition, information on biochemical risk markers can be used to optimize the clinical management of patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Karaganda Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05704569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing